Slide 1: Uscom
Slide 2: Annual General Meeting 2018
ANNUAL GENERAL MEETING 2018 WELCOME Rob Phillips
Slide 3: Agenda
AGENDA CHAIRMAN’S PRESENTATION Financial, Operational, Product and Uscom China 2018 RESULTS Growth to Meet Demand 2019 STRATEGY More Products, More Markets and More Sales PROCEEDINGS Resolutions QUESTIONS Investors
Slide 4: The Uscom Board
THE USCOM BOARD Prof Rob Phillips Mr Christian Bernecker Mr Brett Crowley EXECUTIVE CHAIRMAN NON-EXECUTIVE NON-EXECUTIVE
Slide 5: The Uscom People
THE USCOM PEOPLE Rob Phillips Nick Schicht Teresa Guo Tina Wu Yvonne Song Denise Pater Rik Denicke George Ferenczi Bea Onal Scarlett Zhang Curt Grosse Daniel Kenig Richard Scott Zsofia Kertesz Hagay Gilad George Tang Miko Wang Andrea Marosan
Slide 6: Introduction
INTRODUCTION Our China activities continue to grow with cornerstone Chinese capital investment, the opening of our China office, the appointment of a Director of China operations and registration of a wholly owned, Beijing based, For Uscom shareholders 2018 was a year of expansion and China subsidia
Slide 7: Uscom: Who We Are, Our Vision, Our Drive
USCOM Who We Are Our Vision Our Drive Uscom are the experts in circulation To improve clinical care in Uscom is driven by a commercial delivering innovative, practice cardiovascular and pulmonary ambition to become a leader in the changing non-invasive medicine by developing new non- global healthca
Slide 8: Our Business
OUR BUSINESS Increasing global complexity - Multiple products across 4 continents Science Manufacturing Sales • Concept • Regulatory (Man) • Regulatory (sales) • IP • Assembly • Regional operations • Prototype • Quality • Management/registrations • Validation • Supply chain • Pricing • Clinical tria
Slide 9: 2018: Growth to Meet Demand
2018: GROWTH TO MEET DEMAND Corporate Products P Secured strategic investment from an P BP+ released and CE certified experienced Chinese bio-investor with strategic P SpiroReporter and BP+ Reporter released connections and understanding of the Chinese P Advanced Haemodynamic Application released me
Slide 10: 2018: Results
2018: RESULTS Income, Expenses, Equity, Assets and Cash 2017 2018 5.4 4.8 4.6 4.5 Total Income 18% to $2.9M 4.2 3.8 Equity 28% to $4.8M 3.5 Assets 19% to $5.4M $M AUD 2.9 2.5 Loss 9% to $2M 2.0 1.8 1.66 Cash 50% to $2.5M Wages 25% to $1.7M R&D Investment approximately $1M Income Expenses
Slide 11: 2018: Regional Sales
2018: REGIONAL SALES Regional Sales % 10 China is the major Uscom market, and will continue to be as we proceed to develop 30 60 opportunities associated with the recently established Uscom China in Beijing China Europe USA
Slide 12: 2018: Product Sales
2018: PRODUCT SALES Product regulatory and sales are proportional NMPA FDA CE USCOM 1A 75% USCOM 1A sales reflect value of full regulatory BP+ 20% Loading Loading SpiroSonic 5% Loading Loading *CFDA recently renamed National Medical Products Administration (NMPA)
Slide 13: Capital Structure
CAPITAL STRUCTURE 813 shareholders $20M 100% $0.21 Uscom Shareholders 137,432,532 shares on issue 3 shareholders hold ~40% 60.962% 10 shareholders hold >65% CAP VALUE FREE FLOAT VWAP 2018 Prof Rob Phillips Mr Steven Meng 17.128% 17.34% Mr Gary Davey 4.57%
Slide 14: UCM Share Price
UCM SHARE PRICE 23 UCM ANNUAL PRICE AND RANGE UCM ANNUAL TRADING VOLUME 35 16.1 25 12.4 M SHARES Cents 15 5.2 5.2 5.0 4.1 5 2012 2013 2014 2015 2016 2017 2018 2012 2013 2014 2015 2016 2017 2018 Maximum Final Minimum The value of corporate acquisitions in 2012 and 2015 (BP+ and SpiroSonic) have yet t
Slide 15: 2018: ASX Announcements
2018: ASX ANNOUNCEMENTS BP+ Uscom Limited Orders by US Tech giant; BP+ USCOM 1A SpiroSonic GSA listing, capital raising, Reporter released; US eHealth study; New heart measures, ICU Physician New US patent; TGA; Euro research cornerstone investment by China CE Mark; BIHS listing; Hypertension study
Slide 16: Uscom China
USCOM CHINA Teresa Guo - Director of China Operations appointed Experienced China investor/partner (~18%) Expanded operations New IP and Patent applications Expanded USCOM 1A distribution Expanded distributor support New China distribution for BP+ and SpiroSonic SpiroSonic and BP+ progressing in NMP
Slide 17: New China IP
NEW CHINA IP Copyrights and Trademarks Uscom China team have been responsible for securing this IP IP is vital for protection of commercial investment in products
Slide 18: Uscom Maternal
USCOM MATERNAL Pre-eclampsia monitor for China market in 2019 Detects Pre-eclampsia as early as 5 weeks, not 20+ weeks like BP monitors. “The majority of deaths due to pre-eclampsia and eclampsia are avoidable through the provision of timely and effective care”. Huge clinical difference in treating
Slide 19: 2018: CE for BP+
2018: CE FOR BP+ BP+ CE for Europe
Slide 20: 500 BP+ Units for Manufacture
500 BP+ UNITS FOR MANUFACTURE First 500 BP+ currently in manufacture to meet orders and anticipated demand 500…..
Slide 21: New Branding
NEW BRANDING Big Bold Clean The Uscom message was focused in 2018, to big, clean and bold messaging
Slide 22: 2018: Summary
2018: SUMMARY G R O W T H O F O P E R AT I O N S T O M E E T D E M A N D • Global expansion preparing the platform for strong manufacturing and sales growth in 2019 • China investor support Uscom (~18%) • Uscom China established in Beijing with new operations, distributors, new products and revenue
Slide 23: 2019: Starting Point
2019: STARTING POINT $3M Revenue Global operations Multiple high value products $2.5M Cash Investor support Intermittent cash flow positive with new products imminent 22% CAGR (6 YRS) Strong China position New products in pipeline $0M Debt 6 year growth history (CAGR 22%) 2018 strategic expansion in
Slide 24: 2019: Strategy and Milestones
2019: STRATEGY AND MILESTONES MORE PRODUCTS, MORE MARKETS AND MORE SALES Drive fundamentals in China, Europe and US markets as we scale up manufacturing and distribution to meet new demand from release of our newly approved products across four continents. With our strong margins these increased rev
Slide 25: 2019: Growing the Pie
2019: GROWING THE PIE MORE PRODUCTS, MORE MARKETS AND MORE SALES Product Sales % 2019 Product Sales % 2018 12% 20% 25% 63% 75% USCOM 1A SpiroSonic BP+ USCOM 1A SpiroSonic BP+ $2.5m $?m
Slide 26: More Than Just a Company
MORE THAN JUST A COMPANY W H Y U S C O M M AT T E R S “Just yesterday I remembered you during my night shift in the NICU. We had two very sick premature neonates with septic shock so we didn’t switched off our USCOM machine for 24 hours adjusting the doses of inotropes and vasopressors. As a result
Slide 27: Conclusion
CONCLUSION “Founding a global medical device company based on sustainable commercial fundamentals, acquiring companies, developing and obtaining regulatory approvals for life-saving devices, establishing centres of global operations, manufacturing, marketing, distribution and sales, and we have chan
Slide 28: General Business
GENERAL BUSINESS § Consideration of Financial Statements and Reports § Questions & Comments on management of the Company § Questions for Auditor § Considerations and voting on resolutions
Slide 29: Financial Statements and Reports
FINANCIAL STATEMENTS AND REPORTS Discussion and adoption To receive and consider the Financial Report of the Company together with the reports of the Directors and the Auditor for the financial year ended 30 June 2018. Questions
Slide 30: Resolution 1: Remuneration Report
RESOLUTION 1 Adoption of the Remunerations Report for the Year Ended 30th June 2018 To consider and, if thought fit, to pass the following advisory resolution of the Company: "That the remunerations Report for the year ended 30th June 2018 (as set out in the Director’s Report) be adopted.” Non-bindi
Slide 31: Resolution 2: Re-election of Christian Bernecker
RESOLUTION 2 Re-election of Director - Mr Christian Bernecker To consider and, if thought fit, to pass the following as an ordinary resolution of the Company: “That Mr Christian Bernecker retires by rotation in accordance with rule 6.4 of the Company’s Constitution and, being eligible for re-electio
Slide 32: Resolution 3: Re-election of Brett Crowley
RESOLUTION 3 Re-election of Director - Mr Brett Crowley To consider and, if thought fit, to pass the following as an ordinary resolution of the Company: “That Mr Brett Crowley, having been appointed a director since the last Annual General Meeting, retires in accordance with the provisions of the Co
Slide 33: Resolution 4: Ratification of Private Placement
RESOLUTION 4 Ratification of Private Placement of Shares on 21 December 2017 To consider and, if thought fit, to pass the following as an ordinary resolution of the Company: “That, for the purposes of ASX Listing Rule 7.4, and for all other purposes, the issue of 22,044,998 shares at an issue price
Slide 34: Resolution 5: Share Rights to Rob Phillips
RESOLUTION 5 Grant of Share Rights to Executive Chairman Rob Phillips To consider and, if thought fit, to pass the following as an ordinary resolution of the Company: “That, for the purposes of ASX Listing Rule 10.14, and for all other purposes, the grant to the Executive Chairman, Assoc. Prof Rob P
Slide 35: Resolution 6: Additional Share Issue Capacity
RESOLUTION 6 Additional Share Issue Capacity Under Listing Rule 7.1A To consider and, if thought fit, to pass the following resolution as a special resolution of the Company: “Th That, pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, shareholders approve the issue
Slide 36: Summary of Proxy Voting
SUMMARY OF PROXY VOTING Resolution For Chair Against Abstain 1 42,348,533 (84.46%) 6,905,170 (13.77%) 885,243 (1.77%) 89,255 2 66,561,510 (89.97%) 6,905,170 (9.33%) 515,879 (0.70%) 60,000 3 66,611,510 (90.04%) 6,905,170 (9.33%) 465,879 (0.63%) 60,000 4 66,352,147 (94.61%) 7,307,716 (10.42%) 465,333
Slide 37: Questions - Thank You
Questions ANNUAL GENERAL MEETING 2018 THANK YOU Rob Phillips